Episode Highlights a Truly Remarkable Patient Story Spanning 79 Years Video features 79-year-old Norma Coles, believed to be ...

Quoin Pharmaceuticals Ltd. has filed a U.S. patent application for new topical formulations aimed at treating several skin diseases, specifically Netherton Syndrome (NS) and Peeling Skin Syndrome.

Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the company’s NETHERTON NOW website “Norma’s ...

A diagnosis of Netherton syndrome was made and the patient was started on antihistamines, emollients, and 10% urea. In our case, the patient presented at age 17 years. The history of his ...

Quoin Pharmaceuticals (QNRX) announced the release of the second episode in its “Living with Netherton” video series, part of the company’s ...

Quoin Pharmaceuticals (QNRX) announces additional highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome ...

Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic Dermatitis Third Quoin Patent Application for Netherton Syndrome If Granted Company ...

Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the company's NETHERTON NOW website ASHBURN, Va., April ...

The parents of a baby who received a liver transplant at the Royal Children’s Hospital have opened up about the miracle phone ...

Quoin Pharmaceuticals Ltd. (QNRX), a specialty pharmaceutical company currently valued at $4.36 million, announced today significant clinical progress in its ongoing Pediatric Netherton Syndrome study ...